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HD 12.58 years-95%CI:10.42-14.73-; TX 10.05-95%CI:7.45-12.65-; APD 6.09-95%CI:
3.43-8.74-; CAPD 10.69-95%CI: 6.14-15.23-.The LLPc-2009- in HD (6,547€-95%CI:
5,727€-7,366€-) was significantly higher (p0.001) than TX (5,079€-95%CI:4,127€-
6,030€-) or APD (4,359€-95%CI:3,064€-5,655€-) but not CAPD (5,785€-95%CI:4,302€-
7,269€-). PPYLtc was higher in HD than in TX, APD or CAPD in all the provided
scenarios. CONCLUSIONS: APD is the alternative with the lowest impact on indi-
rect costs due to morbidity. Besides, TX recipients also have higher rates of em-
ployment than HD and require less disability benefits.
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OBJECTIVES: Little information is available on the prevalence of post-transplant
events and resource utilization associated with such events in renal transplant (RT)
patients in clinical practice in Germany. The PORTRAIT study aims to describe the
health care resources used and to estimate the cost of managing post-transplant
patients using observational data from transplant databases and physician ques-
tionnaires from transplant centers across Europe. Aggregated study results have
been previously communicated; this abstract describes the results from two Ger-
man centers. METHODS: A retrospective observational study was undertaken in
which resource usage over three years was employed to derive costs from a third
party perspective, with results stratified by glomerular filtration rate (GFR) status at
one-year post transplant. Descriptive statistics were used to detail medical re-
source use and its costs. Post-transplant events considered were: hospitals stays,
delayed graft function, outpatient appointments, laboratory tests, anaemia, hyper-
tension, dyslipidaemia and infections. Immunosuppressant drug costs were not
considered in this analysis. RESULTS: Four hundred and fourteen patients from
both sites were included in the analysis. The total three-year cost of post-trans-
plant care by GFR at one year varies from a minimum of €20,632 per patient to a
maximum of €43,163 per patient. The average three-year costs decrease as a result
of improved graft functioning status (increased GFR) at one year. The average
three-year costs for a patient with a GFR45mL/ min/1.73 m2 at one year are 40%
lower than those patients with a GFR30 mL/ min/1.73 m2. CONCLUSIONS: In line
with the multinational results, the German results provide evidence that post-
transplant resource usage in a real-life treatment setting increases as post-trans-
plant renal function worsens. Therefore management strategies that promote re-
nal function post transplant are likely to provide important resource savings to the
health care system.
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OBJECTIVES: Overactive bladder syndrome (OAB) is a urological condition defined
by a set of symptoms including urgency, with or without urge incontinence, usually
with frequency and nocturia. Our aim was to assess the productivity and costs of
women with OAB in Hungary.METHODS: Cross-sectional survey was performed in
5 urology/gynecology outpatient centres. Demographic and clinical characteristics
were recorded. Medication, health and informal care utilisation were surveyed for
the past 12 months. The Work Productivity and Activity Impairment questionnaire
(WPAI) was used to assess productivity. Cost calculation was performed from the
societal perspective and human capital approach was used. RESULTS: Sixty-six
women with mean age of 56.9 (SD12.4) years participated in the study, 3 (5%)
singles, 38 (58%) married, 14 (21%) divorced and 11 (17%) widows. Forty-six (70%)
were in menopause and 45 (69%) were overweighted. Patients have had symptoms
for 6.6 (SD6.2) years in average, 62 (94%) had incontinence of whom 41 (66%)
experienced incontinence episodes daily and 30 (48%) used incontinence pads.
Twenty-six patients (39%) were taking medication for OAB and 22 (33%) had anti-
biotic treatment due to urinary symptoms in the past year. Patients had diverse
diagnostic procedures (e.g. ultrasound: 98%, cystometry 49%, uroflow 64%, cystos-
copy 20%), 10 (15%) were admitted to hospital due to urinary problem. Twenty-
three (35%) patients were working and 2 of them were on sick-leave in the past
year. WPAI results of active workers were: abstenteeism 0.04%, presenteeism
44.6%, impaired activity 48.2%, this latest was 50.7% for non-workers. Total costs
were €340/patient/year (conversion €1275.4 HUF), rate of direct medical, direct
non-medical and indirect cost was 92.6%, 6.8% and 0.6%, respectively.
CONCLUSIONS: Our study is the first to offer data on productivity and costs of
patients with OAB in Hungary. Results suggest that presenteesm is a major prob-
lem and direct medical costs (diagnostics, drugs) are dominant.
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OBJECTIVES: Complications are common following kidney transplantation. The
French Hospital National Database (PMSI) allows patients follow-up through their
hospitalization reports. This study assessed 4-year incidences of complications
after kidney transplantation and estimated their economic impact, in particular
renal complications.METHODS: From the years 2006-2010, hospitalization data for
all patients with kidney transplantation in year 2006 were extracted. Patients’ hos-
pital stays were followed during a period of 4 years. Major hospitalizations of in-
terests were pooled in renal, cardiovascular and infectious complications. Renal
complications were detailed in graft loss, acute renal insufficiency (ARI), acute
rejection (AR), recurrence of initial nephropathy (RIN), chirurgical complication
and, others. Incremental costs were estimated by subtracting transplantation-year
mean cost of patients without any renal complications to the one of those with
renal complications the same year. Mean annual costs of patients with graft loss
were assessed separately for each year. Costs were calculated according to the 2010
National Hospital Tariff and National Scale. RESULTS: A total of 2392 patients with
kidney transplantation in 2006 were identified. A total of 61.5% were males and
mean age was 45.0(14.9) years old. 4-year cumulative incidences of renal, cardio-
vascular and infectious complications were 54.8% (n1,311), 20.8% (n498) and
19.8% (n474). Incidences of ARI, AR, RNI, chirurgical complication and, others
renal complications were 24.5%, 21.1%, 4.1%, 3.1% and 22.4%, respectively. Com-
pared to other patients without any renal complication (First-year mean costs:
€25,170; Q1:€17,341–Q3:€27,649), the corresponding incremental costs for renal
complications were €7,046, €10,376, €10,238, €7,874 and, €5,668. During the 4-year
period, graft loss occurred in 4.4% patients. Annual mean costs of graft loss for the
first, second, third and fourth years were €32,159 (Q1:€11 723–Q3:€41,890) (n105),
€19,085 (n64), €25,269 (n52) and, €20,780 (n41), respectively. CONCLUSIONS:
After transplantation, short-term renal complications are frequent and expensive.
Intensive interventions on renal preservation and graft loss prevention are needed.
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OBJECTIVES: To evaluate the impact of treating urge urinary incontinence (UUI) on
health care resource utilization, productivity, activity impairment, and associated
costs. METHODS: The study used data (N75,000) from the 2011 National Health
and Wellness Survey, a self-administered, Internet-based questionnaire of a na-
tionwide sample of adults (age 18). Respondents with UUI or MUI were identified
via 3 Incontinence Questions. Respondents with stress urinary incontinence only,
prostate cancer, or (medication for) benign prostatic hyperplasia, were excluded.
UUI/MUI respondents were categorized as using prescription medication (Rx users)
for overactive bladder (OAB) and non-Rx users (who never used Rx and whose
condition reportedly interfered with life activities or was difficult to manage). Out-
come measures included health care utilization (type/number of resources used
within the past 6 months) and Work Productivity and Activity Impairment ques-
tionnaire-based scores. Direct and indirect costs were estimated using 2010 labor
and 2008 medical expenditure data sources. Generalized linear models predicted
resource use and productivity as a function of treatment status, adjusting for co-
variates (e.g., sociodemographics, BMI, OAB severity, UUI vs. MUI, and comorbid
status) that may also predict impairment. RESULTS:Among 1,190 UUI/MUI respon-
dents, 481 were defined as Rx and 709 as non-Rx users. Rx (vs. non-Rx) users were
more likely to be female (80.7% vs. 70.0%), older (mean62.7 vs. 53.1), non-Hispanic
White (82.3% vs. 69.7%), college educated, health-insured (94.6% vs. 81.7%), unem-
ployed/retired (72.6% vs. 57.7%), and reporting more moderate-to-severe OAB
(70.9% vs. 52.6%; all p0.05). Adjusting for covariates, Rx (vs. non-Rx) users had
lower activity impairment (41.1% vs. 46.8%), more provider visits (7.42 vs. 5.60) and
costs ($18,175 vs. $13,679), and higher total direct costs ($27,291 vs. $21,493), all
p0.01. CONCLUSIONS: UUI patients using, vs. never using, prescription medica-
tion reported lower activity impairment but higher direct costs. The findings may
inform the degree to which UUI pharmacotherapy affects health outcomes.
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OBJECTIVES: Comparing the costs of Solifenacin, Oxybutynin, Trospium chloride,
Tolterodine, Propiverine, and Darifenacine for the treatment of overactive bladder
(OAB) and incontinence in Germany. DATA AND METHODS: The cost-study is
based on a unique sickness fund dataset of 2.9 million insured persons which
included pharmaceutical, outpatient, inpatient, medical aids as well as remedies
data in 2009. 25,896 persons received anticholinergics and were classified as OAB
patients. 4,152 of these patients also suffered from incontinence. Multiple linear
regression models were performed to control for age and gender effects. Further-
more, a general approach (all costs were included) as well as a specific approach
(only costs associated with OAB were considered) were used. RESULTS: OAB pa-
tients caused additional costs of €2,492 using the general and €782 using the spe-
cific approach compared to Non-OAB patients. Patients treated with Propiverine
(€1,854) had the lowest additional costs under the general approach and patients
treated with Darifenacine (€3,230) the highest. In the specific approach, patients
treated with Propiverine (€691) had the lowest additional costs and patients treated
with Tolterodine (€1,124) the highest. In the special case of incontinence, patients
treated with Solifenacin have shown, by far, the lowest additional costs using
either approach (€3,216; €1,320). These results are mainly driven by the lower costs
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of aids, especially due to the lower pad usage. Patients treated with Trospium
chloride (€5,409) exhibited the highest costs using the general approach and pa-
tients treated with Tolterodine (€2,198) incurred the highest costs using the specific
approach. All results were highly significant (p0.01). CONCLUSIONS: This study
compares the costs of six anticholinergics for the treatment of OAB and inconti-
nence in Germany. OAB patients treated with Propiverine and incontinent patients
treated with Solifenacin have shown the lowest additional costs. For both patient
groups Tolterodine is associated with the highest additional cost of treatment.
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OBJECTIVES: Once daily tacrolimus (OD) revealed better compliance and adher-
ence in post-transplant patients compared to twice daily tacrolimus (BD). Higher
adherence on immunosuppressant therapy revealed lower rate of rejection, hence
lower consumption of dialysis and re-transplantation. We assessed cost-effective-
ness of tacrolimus OD vs. tacrolimus BD in treatment of post-renal transplant
patients in 15 year horizon. METHODS: We developed a Markov cohort model
(using TreAge PRO 2012) with 1-year cycle length with Life-Years-Gained (LYG) as
an outcome; the model reflects health insurances’ perspective. We used literature
derived time-dependent probabilities of transitions among particular health states
(incl. mortality). Patients enter the model after successful kidney transplantation.
We identified following health states: Graft survive, Acute graft rejection (AR),
Post-rejection, Dialysis, Re-transplantation. Patients may Die from each state. Drug
acquisition cost of tacrolimus OD was 10% higher compared to BD, other costs of AR
(1,799€), dialysis (33,675€) and transplantation (16,631€) were derived by an expert
panel and local pricing lists. The costs and outcomes were discounted by 3% rate.
We performed One-Way-Sensitivity (OWSA) and Probabilistic-Sensitivity (PSA)
analyses using 20% deviation from base-case. RESULTS: The model predictability,
in term of patients’ survival within 15 year horizon, was validated according to
mortality data in several kidney transplant patients’ registries. The deterministic
results in 15 year horizon showed that tacrolimus OD generated costs of 67,457€
(10.714 LYG) and tacrolimus BD 68,316€ (10.581 LYG), tacrolimus BD revealed incre-
mental costs of 859€ and -0.133 LYG. PSA showed 96.7% probability of tacrolimus
OD being dominant and 3.3% below defined threshold of 1 GDP/ capita in the Czech
Republic. CONCLUSIONS: Tacrolimus OD is dominant intervention (lower costs
and simultaneously higher outcomes) despite 10% higher acquisition costs com-
pared to tacrolimus BD. OWSA showed that the results were the most sensitive on
tacrolimus acquisition cost, compliance rate and cost of dialysis.
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OBJECTIVES: Standard of care and use of immunosuppressive drugs in renal trans-
plant recipients have changed in recent years. We provide an updated pharmaco-
economic model which uses state of the art methodological standards in phar-
macoeconomics based upon current evidence. To our knowledge this is the first
analysis in transplant medicine using a mixed treatment comparison (MTC)
analysis. METHODS: An established Markov model was updated comparing four
currently used immunosuppressive regimens (TR) which reflect real life use in
clinical transplant practice not necessarily restricted to an approved label: “Siroli-
mus  early withdrawal of Ciclosporin  Steroids” (TR1), “Sirolimus-early-transi-
tion” (TR2), “Everolimus-early-transition” (TR3) and “Tacrolimus low doseMyco-
phenolate mofetil Steroids” (TR4). Patients could experience nine different states
of post-transplant adverse events, discontinue TR or die. Transition probabilities
were based on a MTC analysis for a 12 month time horizon. Costs and benefits were
modeled from the perspective of the German statutory health insurance (SHI).
Robustness of the model was tested in extensive sensitivity analyses. RESULTS:
“Sirolimus early transition” (TR2) yields the highest life years (LY) (0.987 LY), while
generating costs of 17,500 Euro for 12 months, slightly more than TR4 (conservative
assumption). TR2 clearly dominates TR 3, a regimen with the second mTOR-inhib-
itor in market, and TR1, the regimen used in the European registration study, in
terms of ICER (incremental cost-effectiveness ratio) in Euro per LY gained for 12
months. Incremental costs of 1,096 Euro for TR2 in comparison to TR4 resulted in
an ICER of 548,000 Euro per QALY gained. CONCLUSIONS: The early transition to
Sirolimus yields favorable results compared to the majority of other regimens in-
vestigated in terms of patient survival and ICER per life year gained. The analysis
corroborates the feasibility of a MTC approach and reflects crucial outcomes which
may support informed clinical decision making.
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OBJECTIVES: There are evidences on the favorable nutritional effects of Ketosteril
in dialysis. Better quality of life and overall survival is attainable through improved
nutritional status, which is also proved in practice. Our aim was to evaluate the
cost-effectiveness of Ketodiet in dialysis in comparison with CKD treatment with-
out Ketosteril. A cohort calculation was presented on the basis of representative
patient attendance data from the Hungarian National Health Insurance Fund Ad-
ministration (HNHIFA). Main outcome of the analysis was incremental cost of life
years gained (LYG). METHODS: HNHIFA database uniquely contains detailed pro-
vision data from the whole Hungarian population of 10 million. All financed health
care providers use the same report structure and reported data are strictly vali-
dated. Our retrospective analyses included data of 2004-2009 for all dialysed pa-
tients with chronic kidney disease (ICD code N17-19) as main diagnosis. Altogether
13 615 patients’ data were included with a mean follow up of 53 months. Ctree●
function of party package in R statistical program was used to determine empirical
survival curves for patients treated with and without Ketosteril. Total costs of
health care services (in- and outpatient care, labs, diagnostics, drugs, medical aids
and sick leave) were taken into consideration. In case of death life years’ loss were
calculated on the basis of Hungarian life expectancy. Costs and outcomes were
discounted with official Hungarian rate of 5%. RESULTS: The average total cost per
patient was 9 596 € higher for Ketosteril arm (39 883 € vs 30 287 €). On the basis of
mortality data we determined lost life years, which showed 0,97 years favour to
Ketosteril (7,24 years vs 8,21 years). ICER of 3 509 460 HUF/LYG represents cost-
effectiveness of Ketosteril compared to other reimbursed health technologies in
Hungary. CONCLUSIONS: Ketosteril therapy of dialysis patients could be a cost-
effectiveness treatment choice based on real world data analysis of Hungarian
patients.
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OBJECTIVES: To assess the cost-effectiveness associated with mirabegron versus
tolterodine extended release (ER) for treating overactive bladder (OAB) from a third
party payer perspective in the US. METHODS: A Markov model was developed to
follow a cohort of OAB patients treated with mirabegron versus tolterodine ER for a
one-year period. Three health states were defined - normal: number of inconti-
nence (I)0 and number of micturitions (M)8; mild-to-moderate: 0I6 and
M16, or I0 and 8 M16; severe: I6 and M16. Evidence from a 12-week clin-
ical trial, comparing mirabegron 50 mg to tolterodine ER 4 mg, was used to estimate
the initial health state distribution, transition probabilities, and discontinuation
rates. Only direct costs were considered, including drug costs (2012 USD) and costs
for OAB complications (2011 USD), with inputs from ReadyPrice® and published
literature. Effectiveness was defined as the proportion of patients in normal state.
Results were expressed as the incremental cost per patient in normal state at the
end of one-year. A subgroup analysis was conducted for patients who discontinued
prior antimuscarinic therapy due to insufficient efficacy at baseline. Univariate and
probabilistic sensitivity analyses were performed. RESULTS: For a one-year hori-
zon, the incremental cost per patient in normal state associated with mirabegron
vs. tolterodine ER was $5,580 (total cost of $4,707 and $4,420 and effectiveness of
17.72% and 12.57% for mirabegron and tolterodine ER respectively) for the total
population. For the subgroup, the incremental cost per patient in normal state was
$2,734 (total cost of $4,664 and $4,451 and effectiveness of 12.76% and 4.96% for
mirabegron and tolterodine ER respectively). Results were robust to the model
assumptions and inputs, while drug cost was the main driver of the model.
CONCLUSIONS: Mirabegron is expected to be a cost-effective option compared to
tolterodine ER, particularly in patients who discontinued prior antimuscarinic
therapy due to insufficient efficacy.
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OBJECTIVES: The INDEPENDENT study showed for the first time a significant re-
duction in mortality associated with Sevelamer, a phosphate binder, compared to
Calcium Carbonate, in stage 3-4 nondialysis-dependent CKD patients. We evalu-
ated the impact on CKD related hospitalizations in order to assess the cost-effec-
tiveness profile from the NHS perspective. METHODS: The INDEPENDENT study
involved 107 (Sev) and 105 (CaC) patients with a 36 months follow-up. Since few of
them started dialysis, we also performed a subgroup secondary analysis on pa-
tients remaining dialysis free (76 vs 63). Individual hospitalizations in Nephrology,
Cardiology and ICU were recorded as well the overall length of stay over the obser-
vation period. Correlated consumption of drugs, such as alpha and beta blockers,
ARBs, ACE inhibitors, calcium channels blockers and erythropoietin, was also as-
sessed. For hospitalizations and drugs, DGR tariffs and hospital acquisition cost
respectively were used. As effectiveness end-point we considered the number of
averted deaths. RESULTS: Calcium-treated patients were associated with greater
frequencies of admission in all departments, thus generating significantly higher
costs. The average savings generated by reduced hospitalizations far exceeded the
acquisition cost of Sevelamer. In case of hospitalization, Sevelamer-treated pa-
tients showed a substantial reduction in the overall length of stay (-5.9 days,
p0.012). Such difference was also present in the secondary subgroup (-5.5 days,
p0.13). After 1000 bootstrap sampling, the primary analysis provided a mean cost
difference of -€2282/ €27 (CI 95%) and mean effectiveness difference of 0.09/
0.006 averted deaths in favor of Sevelamer. Similar figures were present in the
secondary subgroup analysis (-€2403 / €28 and 0.15 / 0.007). Sevelamer
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